Psoriasis and Its Impact on Quality of Life Among Psoriatic Patients

This work aimed to study some epidemiological features and the clinical profile of patients having psoriasis visiting the Dermatology and Venereology departments of Tanta University Hospitals and to assess the impact of disease on their quality of life.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Psoriasis Quality of Life Skin Diseases Skin Diseases, Papulosquamous Skin and Connective Tissue Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Tanta University

Tanta, Al Gharbia, 31739, Egypt

About this study

Psoriasis is a genetically determined, systemic immune-mediated inflammatory disease that affects predominantly the skin and joints. It is now recognized as a systemic disease, which is associated with multiple comorbidities, including diabetes, hypertension, obesity, and major cardiovascular adverse events. These can shorten the lifespan of patients with severe disease by up to 5 years.

The presentation of psoriasis varies from dusky red scaly papules to raised plaques on the elbows, knees, or scalp to superficial pustules dispersed on the palms or soles or, in rare cases, widespread pustules all over the body. The plaque, guttate, small plaque, inverse, erythrodermic, and pustular forms of psoriasis are among the clinical spectrum's variants. Psoriasis can be diagnosed clinically. However, a skin biopsy may be required for cases in which the presentation is not typical.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Psoriatic patients of both genders aged ≥18 years old.
Patients accepted to be enrolled in this study.

Exclusion criteria

Patients below 18 years old.

Treatment and study plan

Quality of Life Assessment

Other

Patients completed the Dermatology Life Quality Index (DLQI), which includes 10 questions and is designed for use in adults.

Each question is scored on a 4-point scale from 0 ("Not at all") to 3 ("Very much") to assess the past seven days, providing a total score ranging from 0 to 30:

0 - 1: No effect at all on patient's life. 2 - 5: Small effect on patient's life. 6 - 10: Moderate effect on patient's life. 11 - 20: Very large effect on patient's life. 21 - 30: Extremely large effect on patient's life.

Primary outcomes

Dermatology Life Quality Index (DLQI)

Time frame: Six months after the survey.

Patients completed the Dermatology Life Quality Index (DLQI), which includes 10 questions and is designed for use in adults.

Each question is scored on a 4-point scale from 0 ("Not at all") to 3 ("Very much") to assess the past seven days, providing a total score ranging from 0 to 30:

0 - 1: No effect at all on patient's life. 2 - 5: Small effect on patient's life. 6 - 10: Moderate effect on patient's life. 11 - 20: Very large effect on patient's life. 21 - 30: Extremely large effect on patient's life.

Sponsors and collaborators

Lead sponsor

Tanta University

Other

Registry information

Official study title

Some Epidemiological Features and Clinical Profile of Psoriasis and Its Impact on Quality of Life Among Psoriatic Patients Attending Tanta University Hospitals

Important dates

Study start: 2023
Primary completion: 2024
Study completion: 2024
First posted: Jul 16, 2026
Registry last updated: Jul 16, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed